U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535606) titled 'A Study to Evaluate ALN-4915 in Adult Healthy Volunteers' on Feb. 26.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: ALN-4915
ALN-4915 will be administered subcutaneously (SC)
DRUG: Placebo
Placebo will be administered SC
Recruitment Status: RECRUITING
Sponsor: Alnylam Pharmaceuticals
Disclaimer: Curated by HT Syndication....